Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yumeng Zhang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Lihua Sun

    School of Business Administration, Shenyang Pharmaceutical University, Shenyang, China

    3 shared publications
  • Minghao Yang

    Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China

    3 shared publications
  • Qiang Su

    Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China

    2 shared publications
  • Yuanhao Sui

    Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, China

    2 shared publications
  • Zhenzhen An

    Department of Pharmacy Administration, School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China

    1 shared publication

Latest Publications

  • Open Access

    Development Quality of China’s Pharmaceutical Manufacturing Industry: A Perspective Based on Multidimensional Evaluation and Spatiotemporal Evolution

    by Zhenzhen An, Minghao Yang, Yumeng Zhang, Lihua Sun

    The pharmaceutical manufacturing industry in China is undergoing a critical transition toward high-quality development, making a systematic assessment of its Development Quality of the Pharmaceutical manufacturing industry (DQPI) essential for evidence-based policy formulation. However, a comprehensive evaluation system incorporating the dimensions of open and green development, as well as a spatiotemporal evolution analysis, remains underdeveloped. To address these gaps, this study develops a five-dimensional evaluation system for DQPI comprising industrial scale, economic benefits, innovation, open development, and green development. Using data from 2011 to 2023 at three spatial scales (national, regional, and provincial), this study applies entropy weight method, coupling coordination degree model, regional differences analysis, and spatial autocorrelation analysis to conduct a multidimensional evaluation and spatiotemporal evolution analysis. The results indicate a significant upward trend in China’s DQPI at the national level, with innovation being the primary driver. However, economic benefits act as a key constraint, and green development has recently declined. Spatially, inter-regional differences emerge as the primary source of overall differences, manifesting as a distinct east–west gradient pattern and a core-periphery structure characterized by high-high and low-low clusters. This study uncovers the key structural challenges: an efficiency-profitability paradox within the innovation-to-benefit transformation, and intensifying regional divergence. To address these, it proposes a synergistic ‘Core Leadership–Periphery Breakthrough’ governance framework, informing the transition of the pharmaceutical manufacturing industry toward high-quality and sustainable development.

  • Open Access

    A Study on the Equity Dilemma and Reform Strategies of Drug Reimbursement in China’s Medical Insurance System

    by Minghao Yang, Yumeng Zhang, Qiang Su, Yuanhao Sui, Lihua Sun

    Background: The continuous expansion of the National Reimbursement Drug List has led to an increasing cost disparity among alternative drugs for the same indications. Under the current proportional reimbursement mechanism, choosing higher-cost treatments often results in higher compensation. Given the lack of empirical evidence on whether income affects the medication choices of insured individuals in the Chinese context, this study aims to evaluate the impact of income levels on drug selection, providing a basis for optimizing the medical insurance reimbursement policy. Methods: This study extracts data from hospitalized patients enrolled in basic medical insurance from the China Health and Retirement Longitudinal Study (CHARLS) database and preprocesses it in Excel. Subsequently, SPSS is used to conduct descriptive statistics, difference analysis, correlation analysis, and regression analysis on the processed data to explore the impact of income levels on drug selection. Results: After controlling for length of hospitalization and hospitalization costs, the regression coefficient for urban employee basic medical insurance participants is β = 0.505 (p < 0.01), and the regression coefficient for new rural cooperative medical insurance participants is β = 0.195 (p < 0.01). This means that, regardless of whether participants are enrolled in urban employee basic medical insurance or new rural cooperative medical insurance, an increase in income will lead to higher hospitalization drug costs. Conclusions: Compared to low-income insured individuals, high-income participants in the basic medical insurance are more likely to choose higher-cost drugs among alternatives, which leads to unfair reimbursement under the current proportional reimbursement system.

  • Open Access

    Reforming China’s Rare Disease Security System: Risk Management Perspectives and a Dedicated Insurance Innovation

    by Yumeng Zhang, Minghao Yang, Qiang Su, Yuanhao Sui, Lihua Sun

    Objectives: Patients with rare diseases in China face extremely high medical expenses. The current coverage framework remains inadequate in terms of coverage depth and proactive risk control, underscoring an urgent need for institutional reform. Methods: This study employs a policy content analysis approach to review the current landscape of rare disease protection in China. Drawing on risk management theory and the health capital model, it constructs an analytical framework to examine potential institutional reforms through the lens of risk response pathways and the efficiency of health investment. Results: The findings reveal that basic medical insurance (BMI) provides limited financial protection for patients with rare diseases. Among China’s 31 provincial-level administrative centers, 24 have set general outpatient reimbursement ceilings under the urban and rural resident basic medical insurance (URRBMI) at 1000 RMB or less. In comparison, 24 cities have set outpatient reimbursement limits under the urban employee basic medical insurance (UEBMI) at 6000 RMB or less. The security system relies predominantly on the BMI, while supplementary mechanisms have failed to provide effective support or continuity in coverage. Current policies are generally reactive, with coverage typically triggered only after a confirmed diagnosis and often lacking early intervention or preventive strategies. Conclusions: China’s rare disease security system urgently requires structural improvements in coverage depth and proactive risk management. The proposed Dedicated Insurance Scheme for Rare Diseases (DISRD) presents a feasible and sustainable model for China’s multi-tiered system of securing rare diseases. It provides valuable institutional insights for other countries and regions seeking to build public health systems with proactive risk control capabilities.